Dec 8 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES INC - ANNOUNCES NEW FINDINGS FOR LEAD INVESTIGATIONAL COMPOUND TH1902 FOR TREATMENT OF SEVERAL ADDITIONAL CANCERS
* THERATECHNOLOGIES INC - CONFIRMED THAT TH1902 COULD BE ADMINISTERED AT THREE TIMES MAXIMUM TOLERATED DOSE (MTD) OF DOCETAXEL ALONE
* THERATECHNOLOGIES INC - TH1902 SHOWS PRE-CLINICAL IN VIVO EFFICACY IN COLORECTAL, PANCREATIC, MELANOMA AND ENDOMETRIAL CANCERS